Orchestra BioMed Holdings, Inc. (OBIO) Stock Forecast
OBIO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $12.43 average of analyst targets
- Upside to target
- +128.0% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.40
- 52-week range
- $3.49 – $6.35
OBIO analyst ratings
7 analystsNumber of analysts at each rating.
OBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.45 | −$0.37 | −$0.40 | −0.4% | 6 |
| Current fiscal year (2026) | −$1.52 | −$1.65 | −$1.46 | −$1.11 | −36.6% | 6 |
| Next fiscal year (2027) | −$1.51 | −$1.80 | −$1.32 | −$1.52 | +0.4% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $103,500 | $90,000 | $141,000 | −88.0% | 6 |
| Current fiscal year (2026) | $451,140 | $378,000 | $700,000 | −98.7% | 7 |
| Next fiscal year (2027) | $600,140 | $360,000 | $1.3M | +33.0% | 7 |
OBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OBIO revenue: reported and forecast
OBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.41 | −$0.41 | −$0.40 | −$0.40 | +4.6% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.50 | −$1.52 | −$1.52 | −$1.52 | −$1.52 | +1.4% | 2 up · 1 down |
| Next fiscal year (2027) | −$1.46 | −$1.52 | −$1.52 | −$1.51 | −$1.51 | +3.5% | 4 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OBIO beat in 9 of 12.
What analysts expect from OBIO
7 analysts cover Orchestra BioMed; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.43, 128.0% above the latest close of $5.45. Analysts expect earnings of −$1.52 per share for 2026, −36.6% from a year earlier. For 2027 the average estimate is −$1.51 per share on revenue of $0.6 million. Orchestra BioMed beat the EPS estimate in 9 of the last 12 quarters.
Related: OBIO income statement, OBIO key metrics, OBIO chart. See the OBIO stock overview for the latest quote and news.
OBIO forecast FAQ
What is Orchestra BioMed's price target?
The average analyst price target for Orchestra BioMed is $12.43, 128.0% above the latest close of $5.45.
Is Orchestra BioMed a buy, hold or sell?
Of 7 analysts covering Orchestra BioMed, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Orchestra BioMed's EPS forecast?
Analysts forecast −$1.52 per share for 2026 (range −$1.65 to −$1.46); for 2027 the estimate is −$1.51.
What is Orchestra BioMed's revenue forecast?
The average revenue estimate for 2026 is $0.5 million, growth of −98.7%; for 2027 it is $0.6 million.
When does Orchestra BioMed report earnings?
Orchestra BioMed is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.40.
Does Orchestra BioMed usually beat earnings estimates?
Orchestra BioMed reported EPS at or above the analyst estimate in 9 of the last 12 quarters.